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ABSTRACT: Deficient chloride transport through cystic fibrosis (CF) transmembrane
conductance regulator (CFTR) causes lethal complications in CF patients. CF is the
most common autosomal recessive genetic disease, which is caused by mutations in the
CFTR gene; thus, CFTR mutants can serve as primary targets for drugs to modulate and
rescue the ion channel’s function. The first step of drug modulation is to increase the
expression of CFTR in the apical plasma membrane (PM); thus, accurate measurement
of CFTR in the PM is desired. This work reports a tandem enrichment strategy to
prepare PM CFTR and uses a stable isotope labeled CFTR sample as the quantitation
reference to measure the absolute amount of apical PM expression of CFTR in CFBE
41o- cells. It was found that CFBE 41o- cells expressing wild-type CFTR (wtCFTR),
when cultured on plates, had 2.9 ng of the protein in the apical PM per million cells; this
represented 10% of the total CFTR found in the cells. When these cells were polarized
on filters, the apical PM expression of CFTR increased to 14%. Turnover of CFTR in
the apical PM of baby hamster kidney cells overexpressing wtCFTR (BHK-wtCFTR) was also quantified by targeted proteomics
based on multiple reaction monitoring mass spectrometry; wtCFTR had a half-life of 29.0 ± 2.5 h in the apical PM. This
represents the first direct measurement of CFTR turnover using stable isotopes. The absolute quantitation and turnover
measurements of CFTR in the apical PM can significantly facilitate understanding the disease mechanism of CF and thus the
development of new disease-modifying drugs. Absolute CFTR quantitation allows for direct result comparisons among analyses,
analysts, and laboratories and will greatly amplify the overall outcome of CF research and therapy.
KEYWORDS: Cystic fibrosis, cystic fibrosis transmembrane conductance regulator, membrane protein quantitation,
quantitative proteomics
1. INTRODUCTION
For cystic fibrosis (CF), the most common autosomal recessive
genetic disease, there is a recent paradigm shift from treating
disease symptoms toward developing drugs that repair
fundamental defects in the anion channel of cystic fibrosis
transmembrane conductance regulator (CFTR).1−3 CFTR is a
member of the ATP-binding cassette (ABC) transporter
superfamily and functions as a cAMP-dependent, protein
kinase-activated Cl− channel in the plasma membrane (PM).
It has five structural domains: two transmembrane domains
(TMD1 and TMD2), two nucleotide-binding domains (NBD1
and NBD2), and a unique regulatory domain (RD). Deletion of
a phenylalanine at position 508 (F508del) is the most frequent
mutation, accounting for ∼90% of the CF population. The
F508del mutation is located in NBD1, putatively interfacing
with TMDs, and impairs coupled domain folding, PM
expression, ion channel function, and protein stability.4,5 The
misfolded mutant is retained inside cells at the endoplasmic
reticulum (ER), and is degraded by the proteasome.6 Evidence
suggests that, during biosynthesis and trafficking of CFTR,
different domains of the protein interact with various
chaperone systems, facilitating the maturation of wild-type
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CFTR (wtCFTR) and the recognition of the F508del mutant.
Thus, F508del expression in the apical PM is minimal;
consequently, F508del CF patients do not have sufficient
CFTR channel activity in epithelial cells in their airways,
intestine, pancreas, sweat ducts, testes, and other fluid-
transporting tissues.7,8
Two major categories of new CFTR modulator drugs are
currently under extensive research and clinical investigations.9
Corrector drugs repair the biogenesis, trafficking, and ultimately
the apical PM expression of the protein, and potentiator drugs
enable the channel function of mutant CFTR proteins in the
PM. Corrector drugs like VX-809 (Lumacaftor) repair folding
and trafficking of CFTR mutants and enhance the apical PM
expression of F508del.2,10,11 The rescue of PM expression of
mutant CFTR, like F508del, by corrector drugs is the first step
toward restoring Cl− channel activity. However, VX-809 has
limited clinical benefit for F508del CF patients, and its
mechanism of action has yet to be fully understood.2,12 In
addition, it is generally agreed that the first generation of CF
drugs has reached an apparent therapeutic ceiling.2,3,13−16 In-
depth analysis of how current investigational drugs work will
provide mechanistic insights for developing future CF
medicines. These studies would be greatly enhanced by
accurate measurements of CFTR and its mutants in cells,
especially in the PM, where the protein performs its vital ion
channel function.
Difficulties in the analysis of CFTR are among the major
challenges for molecular investigations of CF drug action.
CFTR is a large, glycosylated, multidomain, and low-abundance
integral membrane protein. In order to evaluate the efficacy of
drug compounds, efficient methods are needed to detect and
quantify changes in PM CFTR expression. Historically, western
blot analysis of CFTR has been the central CFTR quantitation
method in CF research;17 newly developed antibodies have
greatly improved the sensitivity of this method.18 However, the
reproducibility, precision, accuracy, and robustness of the
method are less than ideal, providing only semiquantitative
measurements, with a relatively large coefficient of variance and
a narrow dynamic range. Furthermore, CFTR aggregates and
degrades during sample preparations, leading to large measure-
ment variations. These critical problems with membrane
proteins present major, intrinsic challenges for analysis.19−21
Other methods for quantifying surface expression of CFTR
require engineered cells [e.g., green fluorescent fusion proteins
(GFP)] and are not directly applicable to primary cells, which
are better systems for testing new experimental drugs.
Technology innovations, from genomics22 to proteo-
mics,23,24 have played important roles in advancing CF research
and therapy. We have developed the first quantitative method
to mitigate the intrinsic analytical problems with full-length
CFTR and use CFTR signature peptides as measurement
surrogates.25 CFTR is digested into peptides that are relatively
easy to prepare for mass spectrometry (MS) quantitation.
CFTR quantified in this work ranges from a few tens of
picograms to low nanograms per million baby hamster kidney
cells overexpressing wtCFTR (BHK-wtCFTR) or human
colorectal adenocarcinoma cells (HT-29).25 A signature peptide
is selected for quantitation by a method of liquid chromatog-
raphy−stable isotope dilution−multiple reaction monitoring
MS (LC−SID−MRM MS). It is the method of choice for
quantifying target proteins in complex biomatrices,26−28 which
is regarded as the MS version of western blot analysis, and has
comparable sensitivity to that of western blot analysis but
superior specificity. MRM MS monitors gas-phase dissociation
reactions of target analytes, which requires sequential detection
of an analyte precursor ion as the reactant followed by one or
several analyte fragment ions as the products; therefore, it is
highly specific and can be applied to complex samples with
minimal component separation. The sensitivity and specificity
afforded by the MRM MS method removes the dependence on
high-quality antibodies for conventional immunoassays of
protein targets like CFTR.18
However, later addition of peptide quantitation reference
standards cannot be used to normalize (1) differential sample
loss during CFTR enrichment (CFTR has low concentration in
the PM, and it is essential to enrich the protein to obtain the
needed quantitation limit) and (2) variations in proteolytic
digestion of CFTR (membrane proteins are difficult to digest
completely).29 Thus, peptide-level quantitation reference
standards are less than ideal for the absolute quantitation of
CFTR. More reliable absolute quantitation of PM CFTR will
enable accurate and precise sample-to-sample, day-to-day,
analyst-to-analyst, and lab-to-lab comparisons of results, similar
to that shown for LC−SID−MRM MS quantitation of plasma
proteins,26 and significantly facilitate the development of new
CF drugs. Herein, we report a general workflow (Scheme 1) for
the enrichment and absolute quantitation of large, low-
abundance CFTR protein (and other membrane proteins) in
the apical PM (broadly referred to as the fraction of PM that is
not in contact with the culture support and thus is accessible to
cell surface biotinylation) of BHK-wtCFTR and CFBE cells.
With a variation of this method, CFTR turnover in the apical




Urea, Tris base, iodoacetamide, acrylamide/bis-acrylamide
solution (40%, 29:1), N,N,N′,N′-tetramethylethylenediamine,
L-leucine, L-lysine, L-arginine, methotrexate, doxycycline,
protease inhibitor cocktail, sodium orthovanadate, 1 M Tris-
Scheme 1. Tandem Enrichment of CFTR in the PM and
Workflow for Targeted Proteomic Quantitation of Its
Absolute Expression
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HCl buffer solution, phosphate buffer saline (PBS, 10×, pH
7.4), Triton X-100, and the anhydrides were purchased from
Sigma-Aldrich (St. Louis, MO). Pierce cell surface protein
isolation kit, dithioerythritol (DTE), β-mercaptoethanol (β-
ME), trifluoroacetic acid (TFA), ammonium bicarbonate,
ammonium persulfate, formic acid, and high-performance
liquid chromatography (HPLC) grade acetonitrile were
purchased from Fisher Scientific (Fair Lawn, NJ). The peptide
CFTR01 was synthesized by AnaSpec (San Jose, CA) or
Peptide 2.0 (Chantilly, VA). Isotopic CFTR01 peptide
(NSILTET[L-13C6
15N]HR was synthesized by Cambridge
Research Biochemicals (Cleveland, UK). 18O-Water (>97%)
was purchased from Cambridge Isotope Laboratories (Andover,
MA) or given as a gift from Olinax (Hamilton, ON, Canada).
Water was obtained from a Milli-Q ultrapure water purification
system (Millipore, Billerica, MA). Proteomics grade recombi-
nant trypsin was purchased from Roche Applied Science
(Indianapolis, IN). Human embryonic kidney cell line
(HEK293F) stably transfected with fused cDNA for wtCFTR
and GFP (HEK293F-D042-JK), HEK293F-wtCFTR, was a gift
from Dr. John C. Kappes (University of Alabama at
Birmingham). A cystic fibrosis bronchial-derived cell line
complimented with a 4.7 kb wild-type CFTR cDNA (CFBE
41o-/pCEP-CFTR N 4.7 kb) and a cystic fibrosis bronchial-
derived cell line complimented with a 4.7 kb F508del CFTR
cDNA (CFBE 41o-/pCEP-CFTR F508del 4.7 kb) were from
Dr. Dieter Gruenert (University of California at San
Francisco).30 The HT-29 cell line was purchased from
American Type Culture Collection (Manassas, VA). Purified
full-length CFTR samples were gifts from Dr. L. J. DeLucas
(University of Alabama at Birmingham) and Dr. J. He
(Accelagen, San Diego, CA). Purification of the later full-
length CFTR sample was performed according to a procedure
developed by Dr. J. R. Riordan at the University of North
Carolina, Chapel Hill. The absolute concentration of this highly
purified CFTR sample was obtained by amino acid analysis, and
this sample was used as the reference standard to quantify
stable isotope labeled CFTR samples prepared in-house (see
the following section). Amino acid analysis for the highly
purified, native CFTR was performed at the Keck Biotechnol-
ogy Resource Laboratory at Yale University. DMEM, Ham’s F-
12, DME/Low media deficient in L-arginine, L-leucine, and L-
lysine, and fetal bovine serum were purchased from Thermo
Scientific HyClone (Logan, UT). Dialyzed fetal bovine serum
was purchased from Life Technologies (Thermo, Carlsbad,
CA).
2.2. Cell Culture and Preparation of Protein Quantitation
Standard
BHK-wtCFTR cells were cultured in DMEM/Ham’s F-12 with
550 μM methotrexate and 10% of each of the following
reagents: fetal bovine serum, pen−strep, nonessential amino
acids, and sodium pyruvate. The heavy isotope labeled, full-
length CFTR was obtained by the method of stable isotope
labeling by amino acids in cell culture (SILAC)31 from BHK-
wtCFTR cells cultured in DME/Low deficient in L-lysine, L-
leucine, and L-arginine supplemented with 550 μM methotrex-
ate, 0.4 mM L-arginine·HCl, 0.8 mM L-lysine·HCl, 0.8 mM L-
leucine-1,2-13C (Cambridge Isotopes, Andover, MA), and 10%
dialyzed fetal bovine serum. Cells grown in this labeled media
were allowed at least 7−8 doublings prior to harvesting. CFBE
41o-/pCEP-CFTR N 4.7 kb cells were grown in MEM medium
with 0.3 g/L L-glutamine, 1 g/L glucose, 2.2 g/L NaHCO3, 10%
fetal bovine serum, 20 mM sodium pyruvate, 10 000 μg/mL
streptomycin, and 10 000 units/mL penicillin. The CFBE cells
were grown in plates or snapwell filters (Sigma-Aldrich, St.
Louis, MO) that were coated with human fibronectin (Fisher
Scientific, Fair Lawn, NJ). The HEK293F-wtCFTR cells stably
transfected with wtCFTR-GFP fused cDNA were cultured
using DMEM with 10% fetal bovine serum, and doxycycline
was added at 0, 0.25, 0.75, or 1.00 μg/mL the night before cell
harvesting.
2.3. Cell Surface Biotinylation and Cell Lysate Fractionation
Surface biotinylation25,32 was performed on cells using the
surface protein isolation kit from Pierce, following the
manufacturer’s instructions. Briefly, cells were first labeled
with a thiol-cleavable, amine-reactive biotinylation reagent
[sulfosuccinimidyl-2-(biotinamido)ethyl-1,3-dithiopropionate
(sulfo-NHS-SS-biotin)] and quenched. The biotinylated cells
were dislodged by trypsinization or scraping from the plates or
filters and subsequently lysed with buffer. The lysis buffer (800
μL) containing 1% (v/v) Triton X-100, 150 mM NaCl, 20 mM
Tris-HCl at pH 7.2, and 1% (v/v) protease inhibitors was used
for the lysis of 12−14 million BHK-wtCFTR cells or 6−8
million CFBE cells. The labeled proteins were captured on
avidin agarose and released using Triton X-100 buffer
containing 50 mM dithiothreitol (DTT).
2.4. Gel-Based Electrophoretic Enrichment (GEE)
Gel electrophoresis was performed using a resolving gel
consisting of 8% acrylamide and 0.2% bis(acrylamide). BioRad
glass plates with 1.0 mm spacer plates and a 10-well comb were
used for analysis of overexpressed CFTR; a single well allowing
for a 20 μL loading volume was sufficient for analysis of
overexpressed CFTR in about 8 μg of total biotinylated protein.
For endogenous CFTR, 1.5 mm spacer plates and a 2-well
comb consisting of 1 preparative well for sample loading (680
μL, 500 μg of total biotinylated proteins) and 1 well for loading
the standard molecular weight protein marker or purified
CFTR were used. For the turnover study, 1.5 mm spacer plates
and a 5-well (120 μL) comb were used. CFTR samples were
mixed with aemmli sample buffer containing 20% (v/v) β-ME
and incubated at 30 °C for 30 min. Gel electrophoresis was
carried out at 200 V constant voltage for 45 min or until the
dye front reached the bottom of the gel.
2.5. Digestion
Gel pieces at the interface between the resolving and stacking
gels (∼1 mm3) were excised for further sample preparation. Gel
pieces were washed (25 mM ammonium bicarbonate in H2O/
acetonitrile), reduced (10 mM DTE), and alkylated (20 mM
iodoacetamide) before trypsinization (20 ng/μL). The resulting
digestion solution was dried via SpeedVac (Savant, Farm-
ingdale, NY) and overnight lyophilization (Labconco, Kansas
City, MO).
2.6. LC−SID−MRM MS
The optimization and data analysis of this work were assisted
by the Skyline software.33 The preparation of stable isotope
reference 18O(Δ4)-CFTR01 and LC−SID−MRM MS quanti-
tation were performed following previously reported proce-
dures.25 Some exceptions were those experiments where CFTR
protein quantitation was accomplished in CFBE and BHK-
wtCFTR cells. In those cases, an Eksigent NanoLC-Ultra 2D+
(Redwood City, CA) was used at a flow rate of 400 nL/min
with a self-pack Picofrit column (New Objective, Woburn, MA)
filled with 2.7 μM diameter, 160 Å pore Halo resin (MacMod,
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Chadds Ford, PA), and the length of resin bed was around 15
cm. Solvent A was composed of 98.8% H2O, 1.0% acetonitrile,
and 0.2% formic acid (v/v), and solvent B was composed of
98.8% acetonitrile, 1.0% water, and 0.2% formic acid (v/v). A
typical running gradient was 1% B at 0 min→ 3% B at 5 min→
30% B at 50 min → 80% B at 59 min → 90% B at 69 min →
1% B at 80 min, with a 10 min equilibration. Samples were
loaded on the trap column at flow rate of 4 μL/min at 1%
solvent B for 10 min. A triple quadruple mass spectrometer was
used, 4000 QTrap from ABSCIEX (Foster City, CA).
Transitions for the native and stable isotope labeled peptides
are summarized in Table 1.
2.7. Peptide Derivatization and Ultrathroughput Multiple
Reaction Monitoring (uMRM) MS34
Following in-gel digestion of the HEK293F-wtCFTR cell lysate,
the N-termini of the peptide mixtures were derivatized with
anhydrides (acetic, propionic, butyric, valeric, or succinic
anhydride). To each sample were added 70 μL of acetonitrile,
70 μL of 1 M ammonium bicarbonate, and 10 μL of the
appropriate anhydride, and samples were incubated on ice for 1
h. Following the incubation, another addition of 100 μL of
acetonitrile, 100 μL of 1 M ammonium bicarbonate, and 10 μL
of the appropriate anhydrate were added. Samples were then
incubated on ice for an additional 2 h. After the chemical
derivatization, the modified peptides were dried and desalted
using hydrophilic−lipophilic-balanced sorbent (HLB, Oasis)
and lyophilized. The resulting five derivatized digests were
combined for a single uMRM MS experiment.
2.8. PM CFTR Turnover Study
In a typical experiment, BHK-wtCFTR cells for each time point
were grown in triplicate in nonisotopic media. At time zero, the
media was aspirated, the cells were washed twice with PBS, and
isotopically labeled media was added as follows: (1) BHK-
wtCFTR media minus arginine, leucine, and lysine and
supplemented with 0.4 mM L-arginine·HCl, 0.8 mM L-lysine·
HCl, and 0.8 mM L-leucine-1,2-13C2 or (2) BHK-wtCFTR
media minus arginine, leucine, and lysine and supplemented
with 0.4 mM L-arginine-13C6·HCl (Cambridge Isotopes,
Andover, MA), 0.8 mM L-lysine-13C6
15N2·HCl (Cambridge
Isotopes, Andover, MA), and 0.8 mM L-leucine. At the
appropriate time, the cells were biotinylated, combined, and
fractionated as previously detailed. After protein digestion,
signature peptides for native and stable isotope labeled CFTR
were quantified by LC−SID−MRM MS.
Table 1. CFTR Signature Peptides and Isotopic Counterparts with Respective Transitions for LC−SID−MRM MS Analysisa
peptide origin sequence transition type
CFTR01 Native NSILTETLHR [M + 2H]2+ → y7, y6, y5
L(Δ4)-CFTR01 SILAC NSI[L-1,2-13C2]TET[L-1,2-13C2]HR
R(Δ6)-CFTR01 SILAC NSILTETLH[R-13C6]
18O(Δ4)-CFTR01 Synthetic, 18O-Labeling NSILT[E-18O2]TLH[R-18O2]
L(Δ7)-CFTR01 Synthetic NSILTET[L-13C615N]HR
CFTR02 Native LSLVPDSEQGEAILPR [M + 2H]2+ → y12, y10, y9
L(Δ6)-CFTR02 SILAC [L-1,2-13C2]S[L-1,2-13C2]VPDSEQGEAI[L-1,2-13C2]PR
R(Δ6)-CFTR02 SILAC LSLVPDSEQGEAILP[R-13C6]
CFTR03 Native ISVISTGPTLQAR [M + 2H]2+ → y8, y7, y6
R(Δ6)-CFTR03 SILAC ISVISTGPTLQA[R-13C6]
CFTR04 Native NSILNPINSIR [M + 2H]2+ → y8, y7, y6
R(Δ6)-CFTR04 SILAC NSILNPINSI[R-13C6]
L(Δ2)-CFTR04 SILAC NSI[L-1,2-13C2]NPINSIR
aΔx denotes a mass increase, i.e., Δ4 means a mass increase of 4 Da for the isotope-labeled peptide compared with the native counterpart.
Figure 1. Gel electrophoretic enrichment (GEE) of large membrane proteins. The large proteins are sampled by slicing the gel piece at the interface
of the stacking gel and the resolving gel (A). Samples loaded are as follows: 1, protein ladder; 2, β-galactosidase; 3, 500 ng of CFTR; 4, 1 μg of
CFTR; 5, 10 μg of BHK-wtCFTR biotinylated fraction; 6, 1 μg of BHK-wtCFTR biotinylated fraction; 7, 30 μg of BHK-wtCFTR Triton X-100
extract; and 8, 3 μg of BHK-wtCFTR Triton X-100 extract. The gel piece (red box) was cut for in-gel digestion (B; other bands were relatively low-
molecular-weight membrane proteins removed by GEE), and the resulting peptides were extracted (C) and analyzed by LC−SID−MRM MS (D).
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3. RESULTS AND DISCUSSION
3.1. General Strategy for Cell-Surface Biotinylation and
GEE for the Tandem Enrichment of Large and
Low-Abundance PM Proteins
Membrane proteins are critical for cells to communicate with
the extra-cellular environment. Receptors and transporters in
the PM thus form the most dominant protein class for
developing drugs to treat human diseases.35 These membrane
proteins are typically large, hydrophobic, and low in abundance.
Preparation of membrane proteins and proteome samples is a
major analytical bottleneck in analysis.19,20 We have thus
designed a novel, broadly applicable workflow to enrich low-
abundance, large membrane proteins by sequential use of (1)
the established method of cell surface biotinylation and (2) a
method of gel electrophoretic enrichment (GEE), which is a
variant of gel electrophoresis (Scheme 1). In this work, we have
established a workflow for enriching PM CFTR and evaluated
experimental variations in major steps of the workflow (see
Supporting Information Text S1, Figure S1, and Tables S1 and
S2).
GEE makes special use of sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) for separation
of protein mixtures. In the GEE method, nongradient gels are
used for protein fractionation, and the gel compositions are
formulated in such a way that proteins larger than a minimum
molecular weight do not migrate appreciably in the resolving
gel. It is a simple but effective approach for enriching high-
molecular-weight proteins (e.g., >150 kDa) in a complex
mixture (Figure 1). For enriching CFTR, the composition for
the resolving gel is 8% acrylamide and 0.2% bis(acrylamide).
This composition slows the migration of large proteins and
limits their location to the interface region of the resolving and
stacking gel while allowing for the electrophoretic migration of
smaller proteins. With or without gel staining, a protein fraction
with a predictable lower cutoff of molecular weight (i.e.,
proteins that have molecular weights higher than a designed
value) can be reproducibly sampled by excising gel slices at a
fixed location near the interface (Figure 1) for subsequent in-
gel digestion and MS analysis.
Expression of CFTR in the PM is low, and the tandem
enrichment strategy made CFTR quantitation possible by LC−
SID−MRM MS,36 without using antibody enrichment of the
protein;25 this is due to both the increase in CFTR
concentration and the decrease in the sample complexity for
MS quantitation. Mutant CFTR proteins, even after therapeutic
intervention, exist in even lower amounts in the PM; thus,
enrichment of PM CFTR is necessary for quantifying the
protein by MS. A study was performed to compare LC−SID−
MRM MS quantitation of CFTR signature peptides prepared
by the tandem enrichment workflow with those in the direct
digestion mixture of the PM subproteome prepared by surface
biotinylation and avidin pull-down for HT-29 cells. Only the
former workflow resulted in confident quantitation, and the
measurement gave 40 fmol of apical PM CFTR per million
cells, equivalent to 23 000 molecules per cell (Figures 1 and 2).
It should be noted that this amount is based on a peptide
quantitation reference standard [18O(Δ4)-CFTR01]25 and thus
represents the lower range of PM CFTR in HT-29 cells (see
later for a discussion on protein vs peptide quantitation
reference standards). Although the GEE method by itself can
be used for preparing CFTR signature peptides from various
protein (mixture) samples containing CFTR, it is necessary to
have the surface biotinylation enrichment in the workflow.
Thus, only matured full-length CFTR (commonly referred to
as Band C37 by the CF research and clinical community) in the
PM is sampled for quantitation; the GEE method does not
separate the nonglycosylated CFTR (commonly referred to as
Band B37) from that which is fully matured.
Another analytical advantage for the GEE method is
compatibility with various solubilizing reagents used for
preparing samples containing CFTR. To enhance solubilization
of membrane proteins, SDS and other detergents are used in
the extraction and digestion buffers. However, the presence of
detergents can interfere with protease activity during protein
digestion and can also affect chromatographic separation and
suppress ionization of resulting peptides. Although the
detergents can be removed after digestion, cleanup of
detergent-containing peptide mixtures can cause significant
sample loss and has varying efficiencies. In contrast, during the
gel-based sample preparations, detergents and other interfering
reagents are removed by extensive washing before digestion. It
has been reported that protein mixtures can be concentrated to
a thin band after a short-running SDS-PAGE; the main purpose
of this practice has been the removal of detergents in
membrane protein preparations for enhanced MS-based
proteomic analysis,38,39 not to enrich low-abundance proteins
based on their size. Compared to the in-solution digestion, the
in-gel digestion also increases the digestion efficiency for
membrane proteins;40,41 this is possibly attributed to the
Figure 2. It is essential to use a tandem enrichment strategy for preparing PM CFTR samples. MRM ion chromatograms are shown for the native
signature peptide (solid line) and the spiked stable isotope reference peptide (dotted line) of digests of HT-29 cell lysate prepared by surface
biotinylation and GEE (A) and surface biotinylation only (B).
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decreased protein aggregation during digestion. By immobiliz-
ing hydrophobic membrane proteins in the gel matrix,
aggregation of membrane proteins and large protein fragments
produced at the initial stage of the protein digestion is likely to
be minimized.
3.2. SILAC CFTR as a Quantitation Reference Standard for
the Absolute Quantitation of PM CFTR
The full-length CFTR quantitation reference standard was
prepared through metabolic labeling using the SILAC
method.31 Lysates of BHK-wtCFTR cells cultured with media
containing leucine-1,2-13C CFTR (seven doublings) were
prepared by a buffer containing Triton X-100. The SILAC
CFTR amount in the Triton X-100 extract was quantified
against a highly purified, full-length native CFTR standard (this
native CFTR could be used as the master reference standard for
different laboratories) using the GEE method for sample
preparation and LC−SID−MRM MS for CFTR quantitation.
Concentration of native CFTR was determined by amino acid
analysis to be 0.175 (±0.025) μg/μL. The quantity of SILAC
CFTR was measured in triplicate using two signature peptides
(CFTR01 and CFTR02). The protein concentration in the
SILAC Triton X-100 extract was determined to be 4.72
(±0.07) ng/μL (Table 2). It should be noted that the SILAC
CFTR reference standard was used as a Triton X-100 extract
directly for quantifying CFTR samples.
A quantitative comparison was performed to examine the
difference in CFTR between using the SILAC CFTR protein
standard and using a stable isotopic synthetic peptide, L(Δ7)-
CFTR01. HEK293F-wtCFTR cells, which overexpress
wtCFTR upon induction with doxycycline at different
concentrations (0, 0.25, 0.50, 0.75, and 1.0 μg/mL), were
used. Apical PM CFTR was prepared by the tandem
enrichment workflow (Scheme 1). One additional quantitation
reference, peptide L(Δ7)-CFTR01, was added to the peptide
mixtures resulting from in-gel digestion. Furthermore, five
different samples were derivatized with different acid
anhydrates (acetic, propionic, butyric, valeric, or succinic
anhydride); with this sample-specific coding procedure, all
five samples were quantified in a single LC−SID−uMRM MS
experiment.34 The signature peptide CFTR01 was monitored
in this study (Table 3; also see Supporting Information Figures
S2 and S3). Expression of native CFTR in these doxycycline-
inducible HEK293F-wtCFTR cells was determined according
to both L(Δ4)-CFTR01 and L(Δ7)-CFTR01. While both data
sets observed increased expression of CFTR, with the increase
in the doxycycline concentration, CFTR amounts measured
according to the peptide standard L(Δ7)-CFTR01 (added after
in-gel-digestion of CFTR) were only 14−17% of the
corresponding measurements based on L(Δ4)-CFTR01,
produced via in-gel digestion of SILAC CFTR (Table 3).
This study shows that for absolute quantitation of membrane
proteins like CFTR, it is essential to use protein standards to
obtain better quantitation accuracy.
The use of an isotopic protein reference allows for
advantageous addition of an internal standard at an early step
of sample preparation. For the PM CFTR quantitation, SILAC
CFTR was added as the reference in the surface biotinylation
fraction of membrane proteins before further sample
preparations. In comparison, conventional LC−SID−MRM
MS uses isotopic reference peptides.25−28,42 For absolute
quantitation of membrane proteins, peptide references are
not acceptable. Membrane proteins are hard to digest; in a
typical experiment, the yield of signature peptide CFTR01 is
only 14−17%, and this yield varies from one sample
preparation to another (Table 3). Furthermore, CFTR is
prone to aggregation and degradation during sample
preparation; for instance, preparation of CFTR for SDS-
PAGE is performed at 30 °C instead of boiling temperature.
Addition of SILAC CFTR before GEE and protein digestion
largely minimized variations in sample preparation and afforded
the absolute quantitation of CFTR in CFBE cells.
Table 2. Preparation of the SILAC CFTR Quantitation Reference Standarda
area CFTR01 area CFTR02 area ratio CFTR01 area ratio CFTR02
sample no. native L(Δ4) native L(Δ6) native/L(Δ4) native/L(Δ6) SILAC CFTR amount (ng)
1 4457 2100 10 080 4703 2.12 2.14 140.8
2 8690 3980 18 850 9263 2.18 2.03 142.9
3 3890 1810 7879 3717 2.15 2.12 140.8
average 141.5
aThe area ratios between the native peptides and heavy isotope labeled peptides were used to calculate the concentration of SILAC CFTR in cell
lysate, which was labeled with leucine-1,2-13C. Highly-purified full-length CFTR (300 ng) was used to calibrate the absolute amount of SILAC
CFTR. Sample volume was 30 μL.
Table 3. Absolute Amounts of PM CFTR for HEK293F-wtCFTR Cellsa
relative area CFTR01 area ratio
doxycycline (μg/mL) native L(Δ4)b L(Δ7)c native/L(Δ4) native CFTR absolute amount (ng)d CFTR digestion efficiency (%)e
0 0 3802 16 350 0 0
0.25 3654 4229 15 640 0.86 130 15
0.75 4405 2110 7337 2.09 313 16
1.00 3279 1103 3723 2.97 446 17
1.25 29 880 7560 30 190 3.95 593 14
aArea ratios (native/SILAC) were used to calculate expressed native CFTR. b150 ng of SILAC CFTR was added to each sample. c500 fmol of
L(Δ7)-CFTR01 was added. dAmount of PM CFTR for each 10 cm plate. eRelative areas for L(Δ4) and L(Δ7) peptides, together with the known
amounts of SILAC CFTR and L(Δ7)-CFTR01, gave measurements for the digestion efficiency for CFTR. These numbers should represent the
lower limits for the digestion efficiency because sample loss during GEE and peptide preparation could also be attributed to the calculated efficiency.
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3.3. Absolute Quantitation of Apical PM Expression of
CFTR in CFBE 41o- Cells
The CFBE cell line is a common model for CF research and
drug development. We performed absolute quantitation of
apical PM CFTR in CFBE 41o- cells grown on plates and
snapwell filters via LC−MRM MS of signature peptides. Three
signature peptides, CFTR01, CFTR02, and CFTR04, were
monitored by LC−SID−MRM MS (Figure 3), but only
CFTR01 and CFTR02 peptides were consistently able to be
quantified for measuring their precursor CFTR protein in the
PM together with CFTR in the cytoplasm (i.e., CFTR in the
Triton X-100 extract after removing PM CFTR). Quantitation
results based on CFTR01 and CFTR02 were comparable
(Table 2). Each sample was repeated with at least three
different biological preparations. Results are summarized in
Table 4. As expected, surface expression of CFTR in CFBE
cells (14.1% of CFTR in the whole cell lysate) grown in
snapwell filters is higher than that of CFBE cells grown in flasks
(10.1%). This is in agreement with semiquantitative western
blot analysis (Supporting Information Figure S4). CFBE cells
grown on snapwell filters mimic airway epithelial cells, with the
air−liquid interface creating a polarized cell environment,
increasing the PM expression of CFTR. The absolute
quantitation method reported in this work will also enable
accurate measurements of CFTR in primary cells. Absolute
quantitation of PM CFTR will set the basis for the comparison
of results and thus will greatly amplify the overall outcome of
CF research and therapy. In reference, high reproducibility for
LC−SID−MRM MS quantitation of protein targets in complex
matrices has recently been shown for sample-to-sample, day-to-
day, analyst-to-analyst, and lab-to-lab comparisons.26
3.4. Turnover of CFTR in the Apical PM
We designed and performed the first quantitative analysis of
CFTR turnover in the PM using stable isotopes. BHK-wtCFTR
cells were originally cultured in native culture media. At time
zero, culture media were switched to SILAC media containing
stable isotope labeled lysine and arginine or leucine; thus,
native CFTR in the PM started to decrease with time, and
SILAC CFTR labeled with the stable isotopes started to appear
and increase. At different time intervals, cells were harvested,
and the protein fraction containing PM CFTR was processed
according to the tandem enrichment workflow (Scheme 1).
Native CFTR in the PM was quantified against the newly
synthesized isotopic CFTR by LC−SID−MRM MS of
signature peptides. The time course for the newly produced
CFTR was followed for up to 60 or 84 h, through two
experiments. The average area ratio of the signature peptides
from the newly incorporated CFTR versus the native CFTR
(isotopic/native) was normalized to the maximum, and then
the percentage of remaining native CFTR (denoted as R in
Figure 4) was calculated. The natural logarithm of R (for data
points up to 48 h; incorporation of isotope labels were
saturated beyond 48 h) was plotted against time and fitted
according to first-order kinetics11,43 with an adjusted R2 of
0.9496. The half-life (t1/2) of native CFTR in the PM was
calculated to be 29.0 ± 2.5 h.
Rescuing CFTR mutant proteins for expression in the apical
PM is only the first step. The rescued mutants have to be stable
in the membrane and perform the channel function for Cl−
ions. It has been recently reported that the CF drug VX-809
can fully rescue the PM expression of F508del, but the lifespan
of the rescued mutant falls short compared with that of
wtCFTR.11 Conventional western blot analysis of CFTR
cannot be applied for turnover studies of PM CFTR. Although
metabolic pulse−chase of radioisotopes provides a useful tool
for this analysis,11 a more convenient method for accurate
measurements of the protein turnover in the PM can be greatly
beneficial to CF research and drug development. The
combination of metabolic stable isotope labeling and
quantitative proteomics is an emerging alternative to radio-
isotope methods.44,45 Under this experimental framework,
coupling the tandem enrichment of CFTR with highly sensitive
Figure 3. LC−SID−MRMMS chromatograms of signature peptides for quantifying CFTR in the apical PM of CFBE cells grown on filters. Peptides
are denoted as in Table 1.
Table 4. Absolute Quantitation and Surface Expression of
CFTR Protein in CFBE 41o- Cells
sample CFTR amount (ng/106 cells) PM expression (%)
plate, biotinylated 2.90 ± 0.03 10.3 ± 0.4
plate, flow-through 25.0 ± 0.8
filter, biotinylated 6.75 ± 0.18 14.1 ± 2.0
filter, flow-through 41.2 ± 4.7
Journal of Proteome Research Article
dx.doi.org/10.1021/pr5006795 | J. Proteome Res. 2014, 13, 4676−46854682
MRMMS has made it possible to measure CFTR turnover (t1/2
= 29.0 ± 2.5 h) in the PM of BHK-wtCFTR cells. In
comparison, a shorter half-life (t1/2 ∼14 h) was recently
reported for CFTR in the whole-cell lysate of the same cell
line.11 These results are in agreement with the observation that
PM proteins degrade more slowly than proteins that do not
reach the membrane.43
4. CONCLUSIONS
Membrane receptors and transporters form the most important
class of protein targets for understanding intercellular
communication and developing new drugs. Recent advances
in MS-based quantitative proteomics, in combination with new
sample preparation workflows, have made it possible to obtain
unprecedented accuracy and precision in membrane protein
measurements. Targeted quantitation of apical PM CFTR
reported in this work exemplifies an important application of
contemporary proteomics technologies, and it will significantly
help with understanding the disease mechanism of CF and
developing future medicine for its treatment.
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